Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $50.00 price target on the stock.
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series